Phase II Clinical Study of JTE-052 - Dose finding study in patients with atopic dermatitis
Phase 2
Completed
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-jRCT2080222835
- Lead Sponsor
- Japan Tobacco Inc.
- Brief Summary
The efficacy and safety of JTE-052 ointment were confirmed in patients with atopic dermatitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 327
Inclusion Criteria
A historical diagnosis of moderate or severe atopic dermatitis
- Modified Eczema Area and Severity Index (mEASI) >= 10
Exclusion Criteria
Patients with active infection at the study drug application site
Use of topical corticosteroids (strongest or very strong) within 28 days before baseline
Use of topical corticosteroids (strong, medium or weak) within 7 days before baseline
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method